Amid ongoing uncertainty in federal research funding, particularly from the National Institutes of Health (NIH), the University of Chicago’s Biological Sciences Division (BSD) has made a significant reduction to its PhD admissions for Autumn 2025. In an email circulated to current BSD students, the administration announced that all invitees who had not yet accepted their offer would have their admission deferred to the 2026–2027 academic year. The message cited the “uncertain national landscape of funding for research, training, fellowships, and medical care” as the primary driver behind this decision.
According to the email, BSD typically plans for an incoming class of around 100 students, using five-year yield averages to estimate acceptance rates. However, as peer institutions reduced their own graduate admissions this cycle, BSD experienced an unexpected increase in acceptances. Despite reducing offers by approximately 20% across its 16 programs, the division found itself on track to exceed its enrollment target, with nearly 40% of applicants still undecided as the April 15 national decision deadline approached.
In response, and in consultation with the BSD Dean, Vice President of Academic Administration and Finance, the University Provost, and the Office of Legal Counsel, the BSD chose to waitlist most of the remaining undecided applicants. The email emphasized that these offers “have not been rescinded,” as those still waitlisted after April 15 will be offered guaranteed admission for Autumn 2026 if they are willing to delay their graduate education by a year to attend UChicago specifically.
With this move, UChicago joins a growing list of R1 universities enacting similar measures. Citing similar uncertainty around federal funding streams, especially those tied to NIH. Institutions such as Harvard, University of Pennsylvania, University of Pittsburgh, Iowa State University, Massachusetts Institute of Technology, Stanford, and University of Washington have recently reduced graduate admissions, paused hiring, or even rescinded offers. With no clear resolution in sight, BSD’s decision may mark a broader shift in graduate education—where even elite research institutions must confront a new era of financial caution, scaled-back growth, and recalibrated expectations around capacity and stability for the foreseeable future.